Back to Search Start Over

Targeting low- or high-normal Carbon dioxide, Oxygen, and Mean arterial pressure After Cardiac Arrest and REsuscitation: study protocol for a randomized pilot trial.

Authors :
Jakkula, Pekka
Reinikainen, Matti
Hästbacka, Johanna
Pettilä, Ville
Loisa, Pekka
Karlsson, Sari
Laru-Sompa, Raili
Bendel, Stepani
Oksanen, Tuomas
Birkelund, Thomas
Tiainen, Marjaana
Toppila, Jussi
Hakkarainen, Antti
Skrifvars, Markus B.
COMACARE study group
Source :
Trials; 10/30/2017, Vol. 18, p1-9, 9p, 2 Color Photographs, 1 Chart
Publication Year :
2017

Abstract

<bold>Background: </bold>Arterial carbon dioxide tension (PaCO2), oxygen tension (PaO2), and mean arterial pressure (MAP) are modifiable factors that affect cerebral blood flow (CBF), cerebral oxygen delivery, and potentially the course of brain injury after cardiac arrest. No evidence regarding optimal treatment targets exists.<bold>Methods: </bold>The Carbon dioxide, Oxygen, and Mean arterial pressure After Cardiac Arrest and REsuscitation (COMACARE) trial is a pilot multi-center randomized controlled trial (RCT) assessing the feasibility of targeting low- or high-normal PaCO2, PaO2, and MAP in comatose, mechanically ventilated patients after out-of-hospital cardiac arrest (OHCA), as well as its effect on brain injury markers. Using a 23 factorial design, participants are randomized upon admission to an intensive care unit into one of eight groups with various combinations of PaCO2, PaO2, and MAP target levels for 36 h after admission. The primary outcome is neuron-specific enolase (NSE) serum concentration at 48 h after cardiac arrest. The main feasibility outcome is the between-group differences in PaCO2, PaO2, and MAP during the 36 h after ICU admission. Secondary outcomes include serum concentrations of NSE, S100 protein, and cardiac troponin at 24, 48, and 72 h after cardiac arrest; cerebral oxygenation, measured with near-infrared spectroscopy (NIRS); potential differences in epileptic activity, monitored via continuous electroencephalogram (EEG); and neurological outcomes at six months after cardiac arrest.<bold>Discussion: </bold>The trial began in March 2016 and participant recruitment has begun in all seven study sites as of March 2017. Currently, 115 of the total of 120 patients have been included. When completed, the results of this trial will provide preliminary clinical evidence regarding the feasibility of targeting low- or high-normal PaCO2, PaO2, and MAP values and its effect on developing brain injury, brain oxygenation, and epileptic seizures after cardiac arrest. The results of this trial will be used to evaluate whether a larger RCT on this subject is justified.<bold>Trial Registration: </bold>ClinicalTrials.gov, NCT02698917 . Registered on 26 January 2016. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
17456215
Volume :
18
Database :
Complementary Index
Journal :
Trials
Publication Type :
Academic Journal
Accession number :
125969966
Full Text :
https://doi.org/10.1186/s13063-017-2257-0